U.S. Might Drop Daily Alcohol Guidelines, Report Says
The Department of Health and Human Services is considering revising its longstanding recommendations on alcohol consumption, Reuters reported Wednesday—but research published over the past year warns that even moderate drinking can lead to health problems, including multiple types of cancer.
New U.S. Dietary Guidelines might soon be issued loosening the longstanding recommendations for ... More daily alcohol use—but researchers still stress the links between alcohol and several types of cancer.
Since 1990, U.S. Dietary Guidelines, which are reviewed every five years and were last updated in 2020, have recommended men limit their drinking to no more than two drinks per day, while women should limit their consumption to one drink per day.
Three unnamed sources familiar with the matter told Reuters the new guidelines, which could be released as soon as this month, would only include a statement encouraging moderation—but this could still be subject to change before the guidelines are released.
Alcohol is associated with increased risk of multiple types of cancer, including mouth, throat, larynx, esophagus, liver, breast and colorectal cancers, according to the National Cancer Institute.
HHS did not immediately return a request for comment from Forbes.
Dr. Silvia Balbo, a researcher at the University of Minnesota School of Public Health and the Masonic Cancer Center, said the proposed new guidelines would be a 'missed opportunity' to help educate the public about alcohol risks. 'The question I always get is, how much is it safe for us to drink?' Balbo told Forbes. 'Having a guideline that in general gives you an idea, a rough idea of what it means to drink in moderation is a good start,' Balbo said. Rather than scrapping the old guidelines, she would recommend expanding the existing guidelines to include better information for consumers. 'I think expanding really on what that means would have been more helpful rather than going towards a more generic and vague indication that's not going to really help people orient themselves in what it means to drink in moderation.' Balbo also pointed to the United Kingdom's National Health Service guidelines, which offer charts and calculators to determine exactly how many units are in different drinks.
Former Surgeon General Vivek Murthy's office issued an advisory report before he left office in January analyzing the risks of cancer associated with alcohol. 'For certain cancers, like breast, mouth, and throat cancers, evidence shows that this risk may start to increase around one or fewer drinks per day,' the report reads, noting that relative risk of developing certain cancers increases for both men and women who consume two or more drinks per day. Balbo said evidence for a connection between heavy drinking and cancer has been known for decades, but researchers are still working to understand how these cancers develop. Balbo's lab works to understand these mechanisms, particularly those that cause head and neck cancers, and her research was cited in the surgeon general's report in January. According to Balbo, alcohol converts into a compound called acetaldehyde as the body metabolizes it, which then harms the cells found in the mouth, which can cause DNA damage. 'If this DNA damage does not get repaired … it just persists and leads to genetic changes and genomic instability,' Balbo told Forbes in an interview.
The surgeon general's report also notes that only 45% of Americans are aware of the cancer risks associated with alcohol. However, 89% understand the link between tobacco and cancer, 81% know about the cancer risks with asbestos, and 91% are aware of the cancer risks from radiation.
In December 2024, a review conducted by the National Academies of Sciences, Engineering, and Medicine found there was 'insufficient evidence to support an association between moderate alcohol consumption and risks of oral cavity, pharyngeal, esophageal, and laryngeal cancers.' The report did note that moderate drinking could pose a higher risk for breast cancer in women. The report has since received heavy pushback from other researchers, including the National Cancer Institute, The New York Times reported in January.
Studies have shown that alcohol consumption increased among most segments of the American population during the COVID-19 pandemic. However, more recent research indicates that younger millennials and Gen Z are drinking less than earlier generations. A Gallup poll published in 2023 indicated that the number of Americans between the ages of 18-34 who consume alcohol occasionally has fallen by 10 percentage points over the last 20 years. Simultaneously, younger Americans who do drink are consuming fewer drinks per week and cutting back on overdrinking, the same report found.
Canada's public health recommendations are close to America's, recommending women drink no more than two drinks per day and men no more than three. The United Kingdom's National Health Service recommends no more than 14 units of alcohol per week—six glasses of wine or six pints of beer spread out over three days or more. The World Health Organization takes a much stronger stance, warning there is no safe level of alcohol consumption at all and categorizing it as a Group 1 carcinogen—alongside asbestos, radiation and tobacco.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
44 minutes ago
- New York Times
Quote of the Day: ‘I Feel Like I've Been Lied To': When a Measles Outbreak Hits Home
'It's still spreading. I'm starting to think this thing has come back to stay.' LYNN DOUGLAS, the nursing director of the Williston Basin School District in North Dakota, on an outbreak of measles, a disease that had not been present in the state in 14 years. Measles has also hit other parts of the U.S.
Yahoo
2 hours ago
- Yahoo
U.S. Supreme Court orders review over religious challenge to New York abortion law
The U.S. Supreme Court on Monday ordered a lower court in New York to reevaluate whether some religious organizations should be excluded from a state mandate that requires employers to provide employee health care plans that include abortion coverage. The ruling from the high court said the case, Diocese of Albany v. Harris, should be sent back to New York courts to be reviewed again in light of an earlier unanimous Wisconsin case related to the Catholic Church groups being denied state tax exemptions. The justices pointed to the Wisconsin case because the New York case poses similar issues about states exempting religious employers and faith-based groups, The Associated Press reported. The New York case stems from a 2017 state mandate that requires health insurance plans provided by employers to include abortion coverage for situations that include rape and incest. The state mandate includes a religious exemption for institutions, but not for religious-affiliated groups. It was challenged by Catholic and Anglican nuns, Catholic dioceses, Christian churches and other faith organizations. They argued the religious exemption is so narrow that it violates the freedom of religion protected under the First Amendment. The most recent order from the Supreme Court is the second time the case has reached the justices after being litigated for years. After the state adopted the mandate in 2017, religious groups challenged it in state court. The appeals court upheld the regulation and the state refused to exempt religious organizations. In 2021, the religious groups appealed the state's ruling to the U.S. Supreme Court. Justices asked New York to reconsider based on its ruling in another case involving religion, Fulton v. Philadelphia. State courts found the Fulton decision was inapplicable to the situation, prompting the groups to bring it to the Supreme Court again. The religious liberty law firm Becket noted in a release that New York's exemption doesn't currently apply to some organizations, including the Carmelite Sisters for the Aged and Infirm and the Teresian Nursing Home because they 'serve the elderly and dying regardless of religious affiliation.' 'New York wants to browbeat nuns into paying for abortions for the great crime of serving all those in need,' Becket Vice President and senior counsel Eric Baxter said in a statement.' Following the Supreme Court's Monday order, the case is headed back to the New York Court of Appeals.
Yahoo
2 hours ago
- Yahoo
Ionis (IONS) Announces Leadership Transition as R&D Veteran Richard Geary Prepares to Retire
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the 10 biotech stocks screaming a buy. On June 12, the company announced the upcoming retirement of Richard Geary, Ph.D., its executive vice president and chief development officer, effective January 2026. Holly Kordasiewicz, Ph.D., currently senior vice president of neurology, will take over the role. Geary has been with Ionis since 1995 and played a pivotal role in bringing six medicines to regulatory approval, including the company's first independently commercialized drug, TRYNGOLZA. A biotechnologist pouring liquid into a test tube and analyzing its components in a lab. Dr. Kordasiewicz, who joined Ionis in 2011, brings over 20 years of experience in R&D, particularly in neurology. She leads the company's neurology program, covering treatments for conditions such as Alzheimer's disease, Angelman syndrome, and Alexander disease. Her work has also contributed to key partnered programs with Biogen, including the development of QALSODY® and IONIS-MAPTRx. As Dr. Geary transitions out of his role, he will continue as a strategic consultant through 2026 to ensure continuity. Ionis leadership praised both Geary's legacy and Kordasiewicz's appointment as a pivotal step in driving the company's commitment to developing transformational therapies for patients with serious diseases. Ionis Pharmaceuticals, Inc. is a U.S.-based commercial-stage biotech company specializing in RNA-targeted therapies. Its approved products include TRYNGOLZA for FCS, WAINUA, and TEGSEDI for ATTRv-PN, SPINRAZA for spinal muscular atrophy, QALSODY for ALS, and WAYLIVRA for rare lipid disorders. The company has a robust pipeline, including late-stage programs like Olezarsen (for hypertriglyceridemia), Donidalorsen (for hereditary angioedema), and Zilganerse (for Alexander disease), along with several mid-stage treatments for neurological and metabolic conditions. Ionis also collaborates with leading pharma firms, including Biogen, GSK, AstraZeneca, Novartis, Roche, and Metagenomi, expanding its reach in developing transformative RNA therapies. While we acknowledge the potential of IONS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None.
